Kestra Medical Technologies Financial Results
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, a 60% increase year-over-year, driven by wearable cardioverter defibrillator (WCD) market expansion and competitive gains. The company reported a GAAP net loss of $44.1 million and increased its full-year fiscal 2027 revenue guidance to $141 million.
- Term
- Q1 2027
- Earnings call
- Sep 14, 2026, 4:30 PM ET
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%. We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”
Brian Webster, President and CEO